Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.4154
-0.0079 (-1.87%)
At close: Feb 24, 2026, 4:00 PM EST
0.4023
-0.0131 (-3.15%)
Pre-market: Feb 25, 2026, 6:53 AM EST
Gossamer Bio Revenue
Gossamer Bio had revenue of $13.29M in the quarter ending September 30, 2025, with 40.23% growth. This brings the company's revenue in the last twelve months to $44.05M, down -58.17% year-over-year. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm)
$44.05M
Revenue Growth
-58.17%
P/S Ratio
2.18
Revenue / Employee
$303,800
Employees
145
Market Cap
96.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 106.83M |
| Codexis | 52.93M |
| Precision BioSciences | 698.00K |
| Cardiff Oncology | 501.00K |
| aTyr Pharma | 190.00K |
GOSS News
- 1 day ago - Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript - Seeking Alpha
- 1 day ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 1 day ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 1 day ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 1 day ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 1 day ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
- 6 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire